Review
Published · Updated · 1 min read
Tocilizumab and anakinra in managing cytokine release syndrome after immunotherapy
What it means for practice
After CAR-T-cell or bispecific antibody therapy, timely recognition of cytokine release syndrome and assessment of its severity are important. Management should account for severity grade and clinical manifestations.
Summary
Clinical context
The article addresses cytokine release syndrome associated with immune effector cell therapies, including CAR-T cells, as well as bispecific antibodies in oncology. Its main emphasis is on recognizing and managing the syndrome. Possible clinical manifestations include fever, hypotension, and organ dysfunction.
Severity assessment and treatment
The article highlights the role of interleukin-6 in the pathophysiology of the syndrome. It discusses tocilizumab and anakinra, alongside symptom management and severity assessment. The management approach takes the severity grade into account rather than focusing solely on the presence of individual symptoms.
Prevention and practical emphasis
The overview covers prophylactic strategies and treatment protocols for different severity grades. The overall aim of this approach is to mitigate risks associated with these advanced therapies in oncology. For clinical practice, the article emphasizes combining timely recognition of manifestations, severity assessment, and appropriate management.
Source
-
Syndrome de relargage cytokinique.
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer
